http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 01 Jun 2026 16:08:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SD+++++++++Apyx+Medical+Corp++++++++++++++++++++/26583580.html si-local-file:///var/storage/secattach/20260601/26583580.html http://www.streetinsider.com/SEC+Filings/Form++SD+++++++++Apyx+Medical+Corp++++++++++++++++++++/26583580.html Mon, 01 Jun 2026 16:08:00 -0400 APYX O.00062975 http://www.streetinsider.com/SEC+Filings/Form++SD+++++++++Apyx+Medical+Corp++++++++++++++++++++/26583580.html si-local-file:///var/storage/secattach/20260601/26583580.html http://www.streetinsider.com/SEC+Filings/Form++SD+++++++++Apyx+Medical+Corp++++++++++++++++++++/26583580.html Mon, 01 Jun 2026 16:08:00 -0400 APYX O.00062975 http://www.streetinsider.com/Press+Releases/Body+by+Apyx+Takes+Center+Stage+at+Miami+Swim+Week+Showcasing+Real+Patient+Transformations+and+Confidence+on+the+Runway/26554973.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.fl.cleter" idsrc="xmltag.org" >CLEARWATER, Fla.</location></span>, <span class="legendSpanClass"><chron>May 27, 2026</chron></span> /PRNewswire/ -- Apyx Medica<u>l</u> Corporation (NASDAQ:APYX) ("Apyx Medical" or the "Company"), the leader in surgical aesthetics marketed and sold as Renuvion^® and the AYON Body Contouring System™ (AYON), will return to <person>Miami Swim Week</person> with its Body by Apyx showcase, an immersive runway experience featuring real patient transformations.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Body+by+Apyx+Takes+Center+Stage+at+Miami+Swim+Week+Showcasing+Real+Patient+Transformations+and+Confidence+on+the+Runway/26554973.html Wed, 27 May 2026 09:51:00 -0400 APYX O.00062975 http://www.streetinsider.com/Press+Releases/Body+by+Apyx+Takes+Center+Stage+at+Miami+Swim+Week+Showcasing+Real+Patient+Transformations+and+Confidence+on+the+Runway/26554973.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.fl.cleter" idsrc="xmltag.org" >CLEARWATER, Fla.</location></span>, <span class="legendSpanClass"><chron>May 27, 2026</chron></span> /PRNewswire/ -- Apyx Medica<u>l</u> Corporation (NASDAQ:APYX) ("Apyx Medical" or the "Company"), the leader in surgical aesthetics marketed and sold as Renuvion^® and the AYON Body Contouring System™ (AYON), will return to <person>Miami Swim Week</person> with its Body by Apyx showcase, an immersive runway experience featuring real patient transformations.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Body+by+Apyx+Takes+Center+Stage+at+Miami+Swim+Week+Showcasing+Real+Patient+Transformations+and+Confidence+on+the+Runway/26554973.html Wed, 27 May 2026 09:51:00 -0400 APYX O.00062975 http://www.streetinsider.com/PRNewswire/Body+by+Apyx+Takes+Center+Stage+at+Miami+Swim+Week+Showcasing+Real+Patient+Transformations+and+Confidence+on+the+Runway/26554973.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.fl.cleter" idsrc="xmltag.org" >CLEARWATER, Fla.</location></span>, <span class="legendSpanClass"><chron>May 27, 2026</chron></span> /PRNewswire/ -- Apyx Medica<u>l</u> Corporation (NASDAQ:APYX) ("Apyx Medical" or the "Company"), the leader in surgical aesthetics marketed and sold as Renuvion^® and the AYON Body Contouring System™ (AYON), will return to <person>Miami Swim Week</person> with its Body by Apyx showcase, an immersive runway experience featuring real patient transformations.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Body+by+Apyx+Takes+Center+Stage+at+Miami+Swim+Week+Showcasing+Real+Patient+Transformations+and+Confidence+on+the+Runway/26554973.html Wed, 27 May 2026 09:51:00 -0400 APYX O.00062975 http://www.streetinsider.com/PRNewswire/Body+by+Apyx+Takes+Center+Stage+at+Miami+Swim+Week+Showcasing+Real+Patient+Transformations+and+Confidence+on+the+Runway/26554973.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.fl.cleter" idsrc="xmltag.org" >CLEARWATER, Fla.</location></span>, <span class="legendSpanClass"><chron>May 27, 2026</chron></span> /PRNewswire/ -- Apyx Medica<u>l</u> Corporation (NASDAQ:APYX) ("Apyx Medical" or the "Company"), the leader in surgical aesthetics marketed and sold as Renuvion^® and the AYON Body Contouring System™ (AYON), will return to <person>Miami Swim Week</person> with its Body by Apyx showcase, an immersive runway experience featuring real patient transformations.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Body+by+Apyx+Takes+Center+Stage+at+Miami+Swim+Week+Showcasing+Real+Patient+Transformations+and+Confidence+on+the+Runway/26554973.html Wed, 27 May 2026 09:51:00 -0400 APYX O.00062975 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Apyx+Medical+Corp+++++++++For%3A+May+21/26535773.html si-local-file:///var/storage/secattach/20260521/26535773.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Apyx+Medical+Corp+++++++++For%3A+May+21/26535773.html Thu, 21 May 2026 16:23:00 -0400 APYX O.00062975 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Apyx+Medical+Corp+++++++++For%3A+May+21/26535773.html si-local-file:///var/storage/secattach/20260521/26535773.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Apyx+Medical+Corp+++++++++For%3A+May+21/26535773.html Thu, 21 May 2026 16:23:00 -0400 APYX O.00062975 http://www.streetinsider.com/Corporate+News/Apyx+Medical+study+shows+cellulite+treatment+improvement+with+dual+approach/26531771.html <p>Apyx Medical Corporation (NASDAQ: APYX) announced publication of clinical study results demonstrating improvement in cellulite and skin laxity using a combination treatment approach. The study, published in Aesthetic Surgery Journal Open Forum, evaluated the use of Avéli for subcision combined with Renuvion technology.</p><p>The prospective study included 22 patients who received a single treatment session combining both modalities. At 180 days post-treatment, up to 81.8% of patients showed improvement in cellulite appearance according to the study results.</p><p>Objective 3D imaging demonstrated measurable reductions in dimple volume, surface area, and depth, with complete resolution in select cases. Histological analysis in a subset of http://www.streetinsider.com/Corporate+News/Apyx+Medical+study+shows+cellulite+treatment+improvement+with+dual+approach/26531771.html Thu, 21 May 2026 08:03:21 -0400 APYX http://www.streetinsider.com/FDA/Apyx+Medical+study+shows+cellulite+treatment+improvement+with+dual+approach/26531771.html <p>Apyx Medical Corporation (NASDAQ: APYX) announced publication of clinical study results demonstrating improvement in cellulite and skin laxity using a combination treatment approach. The study, published in Aesthetic Surgery Journal Open Forum, evaluated the use of Avéli for subcision combined with Renuvion technology.</p><p>The prospective study included 22 patients who received a single treatment session combining both modalities. At 180 days post-treatment, up to 81.8% of patients showed improvement in cellulite appearance according to the study results.</p><p>Objective 3D imaging demonstrated measurable reductions in dimple volume, surface area, and depth, with complete resolution in select cases. Histological analysis in a subset of http://www.streetinsider.com/FDA/Apyx+Medical+study+shows+cellulite+treatment+improvement+with+dual+approach/26531771.html Thu, 21 May 2026 08:03:21 -0400 APYX http://www.streetinsider.com/Press+Releases/New+Study+Shows+Significant+Improvement+in+Cellulite+and+Skin+Laxity+with+Advanced+Minimally+Invasive+Treatment+Utilizing+Av%C3%A9li%C2%AE+and+Renuvion%C2%AE/26531687.html <p align="justify">CLEARWATER, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- <strong>Apyx Medical Corporation (Nasdaq: APYX)</strong> (the “Company” or “Apyx Medical”), the leader in surgical aesthetics products marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the publication of new clinical data in <em>Aesthetic Surgery Journal Open Forum</em> highlighting a promising approach to improving cellulite and skin laxity, two of the most common aesthetic concerns among women. The prospective investigator initiated clinical study(1) evaluated a combination treatment approach utilizing <strong>Avéli</strong><strong>®</strong> (Tiger Aesthetics Medical, LLC) for targeted subcision to disrupt fibrous septae, followed by <strong>Renuvion</strong> to http://www.streetinsider.com/Press+Releases/New+Study+Shows+Significant+Improvement+in+Cellulite+and+Skin+Laxity+with+Advanced+Minimally+Invasive+Treatment+Utilizing+Av%C3%A9li%C2%AE+and+Renuvion%C2%AE/26531687.html Thu, 21 May 2026 08:00:00 -0400 A.06822034 APYX O.00062975 O.20026344 http://www.streetinsider.com/Press+Releases/New+Study+Shows+Significant+Improvement+in+Cellulite+and+Skin+Laxity+with+Advanced+Minimally+Invasive+Treatment+Utilizing+Av%C3%A9li%C2%AE+and+Renuvion%C2%AE/26531687.html <p align="justify">CLEARWATER, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- <strong>Apyx Medical Corporation (Nasdaq: APYX)</strong> (the “Company” or “Apyx Medical”), the leader in surgical aesthetics products marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the publication of new clinical data in <em>Aesthetic Surgery Journal Open Forum</em> highlighting a promising approach to improving cellulite and skin laxity, two of the most common aesthetic concerns among women. The prospective investigator initiated clinical study(1) evaluated a combination treatment approach utilizing <strong>Avéli</strong><strong>®</strong> (Tiger Aesthetics Medical, LLC) for targeted subcision to disrupt fibrous septae, followed by <strong>Renuvion</strong> to http://www.streetinsider.com/Press+Releases/New+Study+Shows+Significant+Improvement+in+Cellulite+and+Skin+Laxity+with+Advanced+Minimally+Invasive+Treatment+Utilizing+Av%C3%A9li%C2%AE+and+Renuvion%C2%AE/26531687.html Thu, 21 May 2026 08:00:00 -0400 A.06822034 APYX O.00062975 O.20026344 http://www.streetinsider.com/Press+Releases/New+Study+Shows+Significant+Improvement+in+Cellulite+and+Skin+Laxity+with+Advanced+Minimally+Invasive+Treatment+Utilizing+Av%C3%A9li%C2%AE+and+Renuvion%C2%AE/26531687.html <p align="justify">CLEARWATER, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- <strong>Apyx Medical Corporation (Nasdaq: APYX)</strong> (the “Company” or “Apyx Medical”), the leader in surgical aesthetics products marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the publication of new clinical data in <em>Aesthetic Surgery Journal Open Forum</em> highlighting a promising approach to improving cellulite and skin laxity, two of the most common aesthetic concerns among women. The prospective investigator initiated clinical study(1) evaluated a combination treatment approach utilizing <strong>Avéli</strong><strong>®</strong> (Tiger Aesthetics Medical, LLC) for targeted subcision to disrupt fibrous septae, followed by <strong>Renuvion</strong> to http://www.streetinsider.com/Press+Releases/New+Study+Shows+Significant+Improvement+in+Cellulite+and+Skin+Laxity+with+Advanced+Minimally+Invasive+Treatment+Utilizing+Av%C3%A9li%C2%AE+and+Renuvion%C2%AE/26531687.html Thu, 21 May 2026 08:00:00 -0400 A.06822034 APYX O.00062975 O.20026344 http://www.streetinsider.com/Press+Releases/New+Study+Shows+Significant+Improvement+in+Cellulite+and+Skin+Laxity+with+Advanced+Minimally+Invasive+Treatment+Utilizing+Av%C3%A9li%C2%AE+and+Renuvion%C2%AE/26531687.html <p align="justify">CLEARWATER, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- <strong>Apyx Medical Corporation (Nasdaq: APYX)</strong> (the “Company” or “Apyx Medical”), the leader in surgical aesthetics products marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the publication of new clinical data in <em>Aesthetic Surgery Journal Open Forum</em> highlighting a promising approach to improving cellulite and skin laxity, two of the most common aesthetic concerns among women. The prospective investigator initiated clinical study(1) evaluated a combination treatment approach utilizing <strong>Avéli</strong><strong>®</strong> (Tiger Aesthetics Medical, LLC) for targeted subcision to disrupt fibrous septae, followed by <strong>Renuvion</strong> to http://www.streetinsider.com/Press+Releases/New+Study+Shows+Significant+Improvement+in+Cellulite+and+Skin+Laxity+with+Advanced+Minimally+Invasive+Treatment+Utilizing+Av%C3%A9li%C2%AE+and+Renuvion%C2%AE/26531687.html Thu, 21 May 2026 08:00:00 -0400 A.06822034 APYX O.00062975 O.20026344 http://www.streetinsider.com/Globe+Newswire/New+Study+Shows+Significant+Improvement+in+Cellulite+and+Skin+Laxity+with+Advanced+Minimally+Invasive+Treatment+Utilizing+Av%C3%A9li%C2%AE+and+Renuvion%C2%AE/26531687.html <p align="justify">CLEARWATER, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- <strong>Apyx Medical Corporation (Nasdaq: APYX)</strong> (the “Company” or “Apyx Medical”), the leader in surgical aesthetics products marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the publication of new clinical data in <em>Aesthetic Surgery Journal Open Forum</em> highlighting a promising approach to improving cellulite and skin laxity, two of the most common aesthetic concerns among women. The prospective investigator initiated clinical study(1) evaluated a combination treatment approach utilizing <strong>Avéli</strong><strong>®</strong> (Tiger Aesthetics Medical, LLC) for targeted subcision to disrupt fibrous septae, followed by <strong>Renuvion</strong> to http://www.streetinsider.com/Globe+Newswire/New+Study+Shows+Significant+Improvement+in+Cellulite+and+Skin+Laxity+with+Advanced+Minimally+Invasive+Treatment+Utilizing+Av%C3%A9li%C2%AE+and+Renuvion%C2%AE/26531687.html Thu, 21 May 2026 08:00:00 -0400 A.06822034 APYX O.00062975 O.20026344 http://www.streetinsider.com/Globe+Newswire/New+Study+Shows+Significant+Improvement+in+Cellulite+and+Skin+Laxity+with+Advanced+Minimally+Invasive+Treatment+Utilizing+Av%C3%A9li%C2%AE+and+Renuvion%C2%AE/26531687.html <p align="justify">CLEARWATER, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- <strong>Apyx Medical Corporation (Nasdaq: APYX)</strong> (the “Company” or “Apyx Medical”), the leader in surgical aesthetics products marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the publication of new clinical data in <em>Aesthetic Surgery Journal Open Forum</em> highlighting a promising approach to improving cellulite and skin laxity, two of the most common aesthetic concerns among women. The prospective investigator initiated clinical study(1) evaluated a combination treatment approach utilizing <strong>Avéli</strong><strong>®</strong> (Tiger Aesthetics Medical, LLC) for targeted subcision to disrupt fibrous septae, followed by <strong>Renuvion</strong> to http://www.streetinsider.com/Globe+Newswire/New+Study+Shows+Significant+Improvement+in+Cellulite+and+Skin+Laxity+with+Advanced+Minimally+Invasive+Treatment+Utilizing+Av%C3%A9li%C2%AE+and+Renuvion%C2%AE/26531687.html Thu, 21 May 2026 08:00:00 -0400 A.06822034 APYX O.00062975 O.20026344 http://www.streetinsider.com/Globe+Newswire/New+Study+Shows+Significant+Improvement+in+Cellulite+and+Skin+Laxity+with+Advanced+Minimally+Invasive+Treatment+Utilizing+Av%C3%A9li%C2%AE+and+Renuvion%C2%AE/26531687.html <p align="justify">CLEARWATER, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- <strong>Apyx Medical Corporation (Nasdaq: APYX)</strong> (the “Company” or “Apyx Medical”), the leader in surgical aesthetics products marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the publication of new clinical data in <em>Aesthetic Surgery Journal Open Forum</em> highlighting a promising approach to improving cellulite and skin laxity, two of the most common aesthetic concerns among women. The prospective investigator initiated clinical study(1) evaluated a combination treatment approach utilizing <strong>Avéli</strong><strong>®</strong> (Tiger Aesthetics Medical, LLC) for targeted subcision to disrupt fibrous septae, followed by <strong>Renuvion</strong> to http://www.streetinsider.com/Globe+Newswire/New+Study+Shows+Significant+Improvement+in+Cellulite+and+Skin+Laxity+with+Advanced+Minimally+Invasive+Treatment+Utilizing+Av%C3%A9li%C2%AE+and+Renuvion%C2%AE/26531687.html Thu, 21 May 2026 08:00:00 -0400 A.06822034 APYX O.00062975 O.20026344 http://www.streetinsider.com/Globe+Newswire/New+Study+Shows+Significant+Improvement+in+Cellulite+and+Skin+Laxity+with+Advanced+Minimally+Invasive+Treatment+Utilizing+Av%C3%A9li%C2%AE+and+Renuvion%C2%AE/26531687.html <p align="justify">CLEARWATER, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- <strong>Apyx Medical Corporation (Nasdaq: APYX)</strong> (the “Company” or “Apyx Medical”), the leader in surgical aesthetics products marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the publication of new clinical data in <em>Aesthetic Surgery Journal Open Forum</em> highlighting a promising approach to improving cellulite and skin laxity, two of the most common aesthetic concerns among women. The prospective investigator initiated clinical study(1) evaluated a combination treatment approach utilizing <strong>Avéli</strong><strong>®</strong> (Tiger Aesthetics Medical, LLC) for targeted subcision to disrupt fibrous septae, followed by <strong>Renuvion</strong> to http://www.streetinsider.com/Globe+Newswire/New+Study+Shows+Significant+Improvement+in+Cellulite+and+Skin+Laxity+with+Advanced+Minimally+Invasive+Treatment+Utilizing+Av%C3%A9li%C2%AE+and+Renuvion%C2%AE/26531687.html Thu, 21 May 2026 08:00:00 -0400 A.06822034 APYX O.00062975 O.20026344 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Apyx+Medical+Corp+++++++++For%3A+May+14/26490422.html si-local-file:///var/storage/secattach/20260514/26490422.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Apyx+Medical+Corp+++++++++For%3A+May+14/26490422.html Thu, 14 May 2026 08:05:00 -0400 APYX O.00062975 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Apyx+Medical+Corp+++++++++For%3A+May+14/26490422.html si-local-file:///var/storage/secattach/20260514/26490422.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Apyx+Medical+Corp+++++++++For%3A+May+14/26490422.html Thu, 14 May 2026 08:05:00 -0400 APYX O.00062975 http://www.streetinsider.com/Corporate+News/APYX+Medical+study+shows+Renuvion+improves+liposuction+outcomes/26490383.html <p>Apyx Medical Corporation (NASDAQ: APYX) announced publication of a retrospective study in Plastic and Reconstructive Surgery - Global Open evaluating patient outcomes following liposuction with and without its Renuvion technology.</p><p>The 113-patient study, led by Pablo D. Huber, MD, found that patients receiving liposuction combined with Renuvion reported higher satisfaction scores compared to those receiving power-assisted liposuction alone. Patients in the Renuvion group reported satisfaction with reduced excess skin appearance at 87.8 versus 73.8 on the Body-Q scale. Among patients who did not undergo abdominoplasty, satisfaction with abdominal appearance was 68.8 versus 45.0.</p><p>The study showed that 30.0% of Renuvion patients required http://www.streetinsider.com/Corporate+News/APYX+Medical+study+shows+Renuvion+improves+liposuction+outcomes/26490383.html Thu, 14 May 2026 08:03:25 -0400 APYX http://www.streetinsider.com/FDA/APYX+Medical+study+shows+Renuvion+improves+liposuction+outcomes/26490383.html <p>Apyx Medical Corporation (NASDAQ: APYX) announced publication of a retrospective study in Plastic and Reconstructive Surgery - Global Open evaluating patient outcomes following liposuction with and without its Renuvion technology.</p><p>The 113-patient study, led by Pablo D. Huber, MD, found that patients receiving liposuction combined with Renuvion reported higher satisfaction scores compared to those receiving power-assisted liposuction alone. Patients in the Renuvion group reported satisfaction with reduced excess skin appearance at 87.8 versus 73.8 on the Body-Q scale. Among patients who did not undergo abdominoplasty, satisfaction with abdominal appearance was 68.8 versus 45.0.</p><p>The study showed that 30.0% of Renuvion patients required http://www.streetinsider.com/FDA/APYX+Medical+study+shows+Renuvion+improves+liposuction+outcomes/26490383.html Thu, 14 May 2026 08:03:25 -0400 APYX http://www.streetinsider.com/Press+Releases/Apyx+Medical+Corporation+Announces+Retrospective+Clinical+Publication+Evaluating+Clinical+Benefit+of+Renuvion%C2%AE+Used+in+Combination+with+Liposuction/26490300.html <p>CLEARWATER, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=usd9RHrXTY4HEJ4Nnw8_0xjSTc_554_sjEIzmNHOslUznUXo22E1zNT7hvCDLTpw8-EOD_F0wvoDtyQa0Y09IZlpRjRI-RUOANZ-d3LEQew=" rel="nofollow" target="_blank">Apyx Medical Corporation</a> (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the publication of a new retrospective investigator-initiated study in <em>Plastic and Reconstructive Surgery - Global Open</em><em>1</em>. The study evaluated patient-reported outcomes following liposuction with and without helium plasma radiofrequency (Renuvion).</p> <p>The results demonstrate that adding Renuvion to liposuction resulted in statistically significant improvements in patient-reported satisfaction with abdominal appearance and excess skin, along with lower rates of abdominoplasty and surgical revisions, http://www.streetinsider.com/Press+Releases/Apyx+Medical+Corporation+Announces+Retrospective+Clinical+Publication+Evaluating+Clinical+Benefit+of+Renuvion%C2%AE+Used+in+Combination+with+Liposuction/26490300.html Thu, 14 May 2026 08:00:00 -0400 A.50216777 APYX O.00062975 O.54516537 http://www.streetinsider.com/Press+Releases/Apyx+Medical+Corporation+Announces+Retrospective+Clinical+Publication+Evaluating+Clinical+Benefit+of+Renuvion%C2%AE+Used+in+Combination+with+Liposuction/26490300.html <p>CLEARWATER, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=usd9RHrXTY4HEJ4Nnw8_0xjSTc_554_sjEIzmNHOslUznUXo22E1zNT7hvCDLTpw8-EOD_F0wvoDtyQa0Y09IZlpRjRI-RUOANZ-d3LEQew=" rel="nofollow" target="_blank">Apyx Medical Corporation</a> (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the publication of a new retrospective investigator-initiated study in <em>Plastic and Reconstructive Surgery - Global Open</em><em>1</em>. The study evaluated patient-reported outcomes following liposuction with and without helium plasma radiofrequency (Renuvion).</p> <p>The results demonstrate that adding Renuvion to liposuction resulted in statistically significant improvements in patient-reported satisfaction with abdominal appearance and excess skin, along with lower rates of abdominoplasty and surgical revisions, http://www.streetinsider.com/Press+Releases/Apyx+Medical+Corporation+Announces+Retrospective+Clinical+Publication+Evaluating+Clinical+Benefit+of+Renuvion%C2%AE+Used+in+Combination+with+Liposuction/26490300.html Thu, 14 May 2026 08:00:00 -0400 A.50216777 APYX O.00062975 O.54516537 http://www.streetinsider.com/Press+Releases/Apyx+Medical+Corporation+Announces+Retrospective+Clinical+Publication+Evaluating+Clinical+Benefit+of+Renuvion%C2%AE+Used+in+Combination+with+Liposuction/26490300.html <p>CLEARWATER, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=usd9RHrXTY4HEJ4Nnw8_0xjSTc_554_sjEIzmNHOslUznUXo22E1zNT7hvCDLTpw8-EOD_F0wvoDtyQa0Y09IZlpRjRI-RUOANZ-d3LEQew=" rel="nofollow" target="_blank">Apyx Medical Corporation</a> (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the publication of a new retrospective investigator-initiated study in <em>Plastic and Reconstructive Surgery - Global Open</em><em>1</em>. The study evaluated patient-reported outcomes following liposuction with and without helium plasma radiofrequency (Renuvion).</p> <p>The results demonstrate that adding Renuvion to liposuction resulted in statistically significant improvements in patient-reported satisfaction with abdominal appearance and excess skin, along with lower rates of abdominoplasty and surgical revisions, http://www.streetinsider.com/Press+Releases/Apyx+Medical+Corporation+Announces+Retrospective+Clinical+Publication+Evaluating+Clinical+Benefit+of+Renuvion%C2%AE+Used+in+Combination+with+Liposuction/26490300.html Thu, 14 May 2026 08:00:00 -0400 A.50216777 APYX O.00062975 O.54516537